Summary
Serum lipid and lipoprotein values of 32 male patients suffering from gout were quantitated and compared with corresponding values of a random control group which did not differ significantly with regard to age, body weight index and socio-economic status. All patients were on therapy with allopurinol which lasted on average for 6 years. The most striking differences between patients and controls were the increased triglyceride and apo B values and the decreased HDL-cholesterol (HDL-C) and HDL-phospholipid (HDL-PL) values in the patient group. The values of total cholesterol, LDL-cholesterol, apo A-I and Lp (a) were not significantly different between patients and controls. The great differences in the ratios of apo B/LDL-C, apo A-I/HDL-C and apo A-I/HDL-PL values suggest that gout is connected with changes in the chemical composition of the major lipoprotein classes. In three normolipemic individuals who were treated for 3 weeks with allopurinol no changes in lipoproteins and apolipoproteins were apparent. The results are discussed in view of the atherosclerosis risk of patients suffering from gout.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berkowitz D (1966) Gout, hyperlipidemia and diabetes interrelationships. JAMA 197:117–120
Wiedemann E, Rose HG, Schwartz E (1972) Plasma lipoproteins, glucose tolerance and insulin response in primary gout. Am J Med 53:299–307
Becker JH (1960) Gout and serum cholesterol. Wis Med J 59:735
Barlow KA (1968) Hyperlipidemia in primary gout. Metabolism 17:189–299
Rondier J, Truffert J, LeGo A, Brouilhet H, Saporta L, Gennes JL De, Delbarre F (1970) Goutte et hyperlipidémies. Rev Eur Clin Biol 15:959–968
Mielants H, Veyes EM, Weerdt A De (1973) Gout and its relation to lipid metabolism. I. Serum uric acid, lipid, and lipoprotein levels in gout. Ann Rheum Dis 32:501–505
Feldman EB, Wallace SL (1964) Hypertriglyceridemia in gout. Circulation 29:508–513
Emmerson BT, Knowles BR (1971) Triglyceride concentrations in primary gout and gout of chronic lead nephropathy. Metabolism 20:721–729
Darlington LG, Scott JT (1972) Plasma lipid levels in gout. Ann Rheum Dis 31:487–489
Frank O (1974) Untersuchungen über die Häufigkeit von Störungen des Lipid- und Kohlenhydratstoffwechsels bei primärer Gicht und symptomloser Hyperurikämie. Wien Klin Wochenschr 86:252–256
Yamanaka H, Watanabe T, Kawai T, Nishioka K, Sakurabayashi I, Mikanagi K (1981) HDL-cholesterol in patients with gout. Ryumachi 21:38–41
Pilger E, Pristautz H, Pfeiffer KH, Kostner GM (1983) Retrospective evaluation of risk factors for peripheral atherosclerosis by stepwise discriminant analysis. Arteriosclerosis 3:57–63
Avogaro B, Bittolo Bon G, Cazzolato G, Quinci GB (1979) Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet I:901–903
Bradby GV, Valente AJ, Walton KW (1978) Serum high-density lipoproteins in peripheral vascular disease. Lancet II:1271–1274
Kostner G, Avogaro P, Cazzolato G, Marth E, Bittolo Bon G (1981) Lipoprotein Lp (a) and the risk for myocardial infarction. Atherosclerosis 38:51–61
Kostner GM (1983) Apolipoproteins and lipoproteins of human plasma: Significance for health and diseases. Adv Lipid Res 20:1–44
Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA (1982) Separation and quantitation of subclasses of human plasma HDL by a simple precipitation procedure. J Lipid Res 23:1206–1223
Kostner GM, Avogaro P, Bittolo Bon GB, Cazzolato G (1979) The determination of high density lipoproteins in the clinical laboratory: A comparison of screening methods. Clin Chem 25:939–946
Sachs L (1978) Angewandte Statistik. Springer, Berlin Heidelberg New York
Pfeiffer KP (1985) Stepwise variable selection and maximum likelihood estimation of smoothing factors of kernel functions for nonparametric discriminant functions evaluated by different criteria. Comp Biomed Res (in press)
Gibson T, Kilbourn K, Horner I, Simmonds (1979) Mechanism and treatment of hypertriglyceridaemia in gout. Ann Rheum Dis 38:31–35
Miller NE, Hammett F, Saltissi S, Rao S, Zeller H Van, Coltart J, Lewis B (1981) Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J 282:1741–1744
Berg K, Børresen AL (1976) Serum-high-density-lipoprotein and atherosclerotic heart Disease. Lancet I:499–501
Hall AP (1965) Correlations among hyperuricemia, hypercholesterinemia, coronary disease and hypertension. Arthritis Rheum 8:846–852
Yü TF, Talbott JH (1980) Changing trends of mortality in gout. Semin Arthritis Rheum 10:1–8
Günther R, Knapp E (1970) Der Einfluß von Allopurinol (Zyloric) auf Harnsäure, Kreatinin, Nüchternblutzucker und Plasmalipide bei Gichtkranken. Wien Klin Wochenschr 82:78–82
Bluestone R, Lewis B, Mervart I (1971) Hyperlipoproteinaemia in gout. Ann Rheum Dis 30:134–137
Gibson T, Grahame R (1974) Gout and hyperlipidaemia. Ann Rheum Dis 33:298–303
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ulreich, A., Kostner, G.M., Pfeiffer, K.P. et al. Serum lipids and lipoproteins in patients with primary gout. Rheumatol Int 5, 73–77 (1985). https://doi.org/10.1007/BF00270300
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00270300